Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
YD Bio Limited ( (YDES) ) just unveiled an update.
On January 20, 2026, YD Bio Limited entered into a binding letter of intent to acquire all shares, assets and business of Taiwan-based Safe Save Medical Cell Sciences & Technology Co., Ltd. via a newly formed offshore holding company, in a transaction valued at NT$839.8 million (about US$26.9 million) to be paid in a mix of cash and new YD Bio shares subject to lock-up periods. The deal, announced publicly on January 29, 2026, would give YD Bio indirect ownership of SSMC’s dendritic cell immunotherapy platform and late-stage clinical programs in glioblastoma and other solid tumors, reinforcing YD Bio’s strategic shift from a collection of assets toward an end-to-end biotechnology ecosystem that spans cancer diagnostics and advanced cell therapies, though closing remains contingent on due diligence, corporate restructuring and other customary conditions targeted for completion by late April 2026.
The most recent analyst rating on (YDES) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on YD Bio Limited stock, see the YDES Stock Forecast page.
Spark’s Take on YDES Stock
According to Spark, TipRanks’ AI Analyst, YDES is a Neutral.
The score is driven primarily by weak financial performance (losses, negative margins, and negative operating/free cash flow), partially offset by low balance-sheet leverage. Technical indicators add downside pressure with the price below key moving averages and a negative MACD, while valuation provides limited support due to loss-making earnings and no dividend.
To see Spark’s full report on YDES stock, click here.
More about YD Bio Limited
YD Bio Limited is a Taiwan-based biotechnology company focused on clinical trials, new drug development, cancer prevention diagnostics, and stem cell and exosome therapies aimed at diseases with high unmet medical need. In addition to its R&D in DNA methylation-based cancer detection and ophthalmologic innovations, the company supplies clinical trial drugs and has expanded into developing and distributing post-market auxiliary products, positioning itself as a vertically integrated player in precision medicine.
Average Trading Volume: 76,964
Technical Sentiment Signal: Buy
Current Market Cap: $863.2M
See more data about YDES stock on TipRanks’ Stock Analysis page.